Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVM0703 in Patients With Acute Respiratory Distress Syndrome
NCT04366115Phase 1Not yet recruiting
- Sponsor
- AVM Biotechnology
- Start
- Dec 2026
- Primary completion
- Dec 2031
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of AVM0703 in acute respiratory distress syndrome (ARDS), coronavirus disease 2019 (COVID-19) and influenza (4 arms), sponsored by AVM Biotechnology. Primary endpoints: Dose-Limiting Toxicities at 12 months and 28-day all-cause mortality. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
AVM0703
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT04366115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04366115.